A monoclonal antibody against the Wnt signaling inhibitor dickkopf-1 inhibits osteosarcoma metastasis in a preclinical model
Open accessAbstract
// Seth D. Goldstein 1 , Matteo Trucco 2 , Wendy Bautista Guzman 1 , Masanori Hayashi 1 and David M. Loeb 1 1 Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA 2 Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Houston, TX, USA Correspondence to: David M. Loeb, email: // Keywords : sarcoma, metastasis, Wnt signaling, DKK-1, mouse model Received : February 24, 2016 Accepted : March 28, 2016 Published : March 31, 2016 Abstract The outcome of patients with metastatic osteosarcoma has not improved since the introduction of chemotherapy in the 1970s. Development of therapies targeting the metastatic cascade is a tremendous unmet medical need. The Wnt signaling pathway has been the focus of intense investigation in osteosarcoma because of its role in normal bone development. Although the role of Wnt signaling in the pathogenesis of osteosarcoma is controversial, there are several reports of dickkopf-1 (DKK-1), a Wnt signaling antagonist, possibly playing a pro-tumorigenic role. In this work we investigated the effect of anti-DKK-1 antibodies on the growth and metastasis of patient-derived osteosarcoma xenografts. We were able to detect human DKK-1 in the blood of tumor-bearing mice and found a correlation between DKK-1 level and tumor proliferation. Treatment with the anti-DKK-1 antibody, BHQ880, slowed the growth of orthotopically implanted patient-derived osteosarcoma xenografts and inhibited metastasis. This effect was correlated with increased nuclear beta-catenin staining and increased expression of the bone differentiation marker osteopontin. These findings suggest that Wnt signaling is anti-tumorigenic in osteosarcoma, and support the targeting of DKK-1 as an anti-metastatic strategy for patients with osteosarcoma.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Activation of the WNT-β-catenin pathway is important during early steps in the osteosarcoma metastatic cascade.
“Activation of the WNT-β-catenin pathway is important during early steps in the metastatic cascade 70,71 .”
From Osteosarcoma (2022) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Mirabello, L., Troisi, R. J., & Savage, S. A. (2009) · Cancer · doi:10.1002/cncr.24121 · Cited by 2,199 · see citing works
WNT signalling pathways as therapeutic targets in cancer
Anastas, J. N., & Moon, R. T. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3419 · Cited by 1,902 · see citing works
Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction
Glinka, A., Wu, W., Delius, H., Monaghan, A. P., Blumenstock, C., & Niehrs, C. (1998) · Nature · doi:10.1038/34848 · Cited by 1,608 · see citing works
Secreted antagonists of the Wnt signalling pathway
Kawano, Y., & Kypta, R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00623 · Cited by 1,584 · see citing works
Function and biological roles of the Dickkopf family of Wnt modulators
Niehrs, C. (2006) · Oncogene · doi:10.1038/sj.onc.1210054 · Cited by 995 · see citing works
Kager, L., Zoubek, A., Pötschger, U., Kastner, U., Flege, S., Kempf-Bielack, B., Branscheid, D., Kotz, R., Salzer-Kuntschik, M., Winkelmann, W., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.132 · Cited by 934 · see citing works
Johnson, J. I., Decker, S., Zaharevitz, D. W., Rubinstein, L., Venditti, J. M., Schepartz, S. A., Kalyandrug, S., Christian, M. C., Arbuck, S. G., Hollingshead, M. G., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1796 · Cited by 856 · see citing works
Maeda, K., Kobayashi, Y., Udagawa, N., Uehara, S., Ishihara, A., Mizoguchi, T., Kikuchi, Y., Takada, I., Kato, S., Kani, S., et al. (2012) · Nature Medicine · doi:10.1038/nm.2653 · Cited by 542 · see citing works
Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?
Anninga, J. K., Gelderblom, H., Fiocco, M., Kroep, J. R., Taminiau, A. H. M., Hogendoorn, P. C. W., & Egeler, R. M. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.05.030 · Cited by 456 · see citing works
Kerbel, R. S. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.213 · Cited by 324 · see citing works
Noncanonical Wnt Signaling through G Protein-Linked PKCδ Activation Promotes Bone Formation
Tu, X., Joeng, K. S., Nakayama, K., Nakayama, K., Rajagopal, J., Carroll, T. J., McMahon, A. P., & Long, F. (2007) · Developmental Cell · doi:10.1016/j.devcel.2006.11.003 · Cited by 314 · see citing works
Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches
CANALIS, E. M. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.154 · Cited by 305 · see citing works
Duchman, K. R., Gao, Y., & Miller, B. J. (2015) · Cancer Epidemiology · doi:10.1016/j.canep.2015.05.001 · Cited by 303 · see citing works
Metastatic osteosarcoma at diagnosis
Mialou, V., Philip, T. O., Kalifa, C., Pérol, D., Gentet, J., Marec‐Bérard, P., Pacquement, H., Chastagner, P. B., Defaschelles, A.-S., & Hartmann, O. (2005) · Cancer · doi:10.1002/cncr.21263 · Cited by 283 · see citing works
Gregory, C. A., Singh, H., Perry, A. S., & Prockop, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300373200 · Cited by 283 · see citing works
Kansara, M., Tsang, M., Kodjabachian, L., Sims, N. A., Trivett, M. K., Ehrich, M., Dobrovic, A., Slavin, J., Choong, P., Simmons, P. J., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37175 · Cited by 272 · see citing works
Heath, D. J., Chantry, A., Buckle, C., Coulton, L., Shaughnessy, J. D., Evans, H., Snowden, J. A., Stover, D. R., Vanderkerken, K., & Croucher, P. I. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081104 · Cited by 251 · see citing works
A review of clinical and molecular prognostic factors in osteosarcoma
Clark, J. C. M., Dass, C. R., & Choong, P. (2007) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-007-0330-x · Cited by 250 · see citing works
Clarke, B. L. (2009) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(09)79307-2 · Cited by 200 · see citing works
Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma
Khanna, C., Fan, T. M., Gorlick, R., Helman, L. J., Kleinerman, E. S., Adamson, P. C., Houghton, P. J., Tap, W. D., Welch, D. R., Steeg, P. S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2574 · Cited by 178 · see citing works
NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma
Zhao, S., Kurenbekova, L., Gao, Y., Roos, A., Creighton, C. J., Rao, P., Hicks, J., Man, T.-K., Lau, C., Brown, A. M. C., et al. (2015) · Oncogene · doi:10.1038/onc.2014.429 · Cited by 139 · see citing works
Osteosarcoma: improvement in survival limited to high-grade patients only
Jawad, M. U., Cheung, M. C., Clarke, J., Koniaris, L. G., & Scully, S. P. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0923-7 · Cited by 102 · see citing works
Wnt Pathway in Osteosarcoma, from Oncogenic to Therapeutic
Cai, Y., Cai, T., & Chen, Y. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24708 · Cited by 96 · see citing works
Making head or tail of Dickkopf
Nusse, R. (2001) · Nature · doi:10.1038/35077199 · Cited by 82 · see citing works
Krause, U., Ryan, D. M., Clough, B. H., & Gregory, C. A. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.67 · Cited by 77 · see citing works
Lee, N., SMOLARZ, A. J., Olson, S. D., David, O., Reiser, J., Kutner, R. H., Daw, N. C., Prockop, D. J., Horwitz, E. M., & Gregory, C. A. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604069 · Cited by 77 · see citing works
Challenges and opportunities in childhood cancer drug development
Norris, R. E., & Adamson, P. C. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3370 · Cited by 65 · see citing works
Duong, L. M., & Richardson, L. C. (2013) · PubMed · Cited by 59 · see citing works
Goldstein, S. D., Hayashi, M., Albert, C. M., Jackson, K. W., & Loeb, D. M. (2015) · Clinical & Experimental Metastasis · doi:10.1007/s10585-015-9738-x · Cited by 45 · see citing works
Self-citationThe Biology of Metastases in Pediatric Sarcomas
Krishnan, K., Khanna, C., & Helman, L. J. (2005) · The Cancer Journal · doi:10.1097/00130404-200507000-00006 · Cited by 44 · see citing works
Chen, C., Zhou, H., Zhang, X., Ma, X., Liu, Z., & Liu, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105414 · Cited by 35 · see citing works
New Approaches to Drug Development in Pediatric Oncology
Adamson, P. C., & Blaney, S. M. (2005) · The Cancer Journal · doi:10.1097/00130404-200507000-00008 · Cited by 19 · see citing works
Dickkopf-1 as a potential therapeutic target in Paget's disease of bone
McCarthy, H. S., & Marshall, M. J. E. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903525720 · Cited by 19 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660 · see citing works
The Osteosarcoma Microenvironment: A Complex but Targetable Ecosystem
Corre, I., Verrecchia, F., Crenn, V., Rédiní, F., & Trichet, V. (2020) · Cells · doi:10.3390/cells9040976 · Cited by 475 · see citing works
Osteosarcoma: A comprehensive review of management and treatment strategies
Jafari, F., Javdansirat, S., Sanaie, S., Naseri, A., Shamekh, A., Rostamzadeh, D., & Dolati, S. (2020) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2020.151654 · Cited by 253 · see citing works
Grinchuk, O. V., Yenamandra, S. P., Iyer, R., Singh, M., Lee, H. K., Lim, K. H., Chow, P. K. H., & Kuznetsov, V. A. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12153 · Cited by 240 · see citing works
Osteosarcoma: Accelerating Progress Makes for a Hopeful Future
Saraf, A. J., Fenger, J. M., & Roberts, R. D. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00004 · Cited by 237 · see citing works
Rationale for targeting the Wnt signalling modulator Dickkopf‐1 for oncology
Kagey, M. H., & He, X. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13894 · Cited by 134 · see citing works
Wnt signaling and Loxl2 promote aggressive osteosarcoma
Matsuoka, K., Bakiri, L., Wolff, L. I., Linder, M., Mikels, A. J., Patiño‐García, A., Lecanda, F., Hartmann, C., Sibilia, M. C., & Wagner, E. F. (2020) · Cell Research · doi:10.1038/s41422-020-0370-1 · Cited by 121 · see citing works
Bone-Targeted Therapies in Cancer-Induced Bone Disease
Sousa, S., & Clézardin, P. (2017) · Calcified Tissue International · doi:10.1007/s00223-017-0353-5 · Cited by 115 · see citing works
Tegavivint and the β-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma
Nomura, M., Rainusso, N., Lee, Y.-C., Dawson, B., Coarfa, C., Han, R., Larson, J. L., Shuck, R., Kurenbekova, L., & Yustein, J. T. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz026 · Cited by 99 · see citing works
Fan, T. M., Roberts, R. D., & Lizardo, M. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00013 · Cited by 90 · see citing works
Zhao, S.-J., Jiang, Y.-Q., Xu, N.-W., Li, Q., Zhang, Q., Wang, S.-Y., Li, J., Wang, Y.-H., Zhang, Y., Jiang, S., et al. (2017) · Oncogene · doi:10.1038/onc.2017.403 · Cited by 89 · see citing works
Dickkopf-1: A Promising Target for Cancer Immunotherapy
Chu, H. Y., Chen, Z., Wang, L., Zhang, Z., Tan, X., Liu, S., Zhang, B., Lü, A., Yu, Y., & Zhang, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658097 · Cited by 85 · see citing works
Monocytes, Macrophages, and Osteoclasts in Osteosarcoma
Kelleher, F. C., & O’Sullivan, H. (2017) · Journal of Adolescent and Young Adult Oncology · doi:10.1089/jayao.2016.0078 · Cited by 81 · see citing works
Drug Discovery of DKK1 Inhibitors
Jiang, H., Zhang, Z., Yu, Y., Chu, H. Y., Yu, S., Yao, S., Zhang, G., & Zhang, B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.847387 · Cited by 79 · see citing works
Wnt signaling in cancer: from biomarkers to targeted therapies and clinical translation
Tufail, M., Jiang, C., & Li, N. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02306-w · Cited by 82 · see citing works
Shinno, N., Kimura, H., Sada, R., Takiguchi, S., Mori, M., Fumoto, K., Doki, Y., & Kikuchi, A. (2018) · Oncogene · doi:10.1038/s41388-018-0179-2 · Cited by 65 · see citing works
Vega, O. A., Lucero, C. M. J., Araya, H., Jerez, S., Tapia, J. C., Antonelli, M., Salazar‐Onfray, F., Heras, F. L., Thaler, R., Riester, S. M., et al. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26011 · Cited by 62 · see citing works
Singla, A. K., Wang, J., Yang, R., Geller, D. S., Loeb, D. M., & Hoang, B. H. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43085-6_8 · Cited by 50 · see citing works
Self-citationDependence receptors – the dark side awakens
Negulescu, A., & Mehlen, P. (2018) · FEBS Journal · doi:10.1111/febs.14507 · Cited by 45 · see citing works
Schott, C. R., Koehne, A. L., Sayles, L. C., Young, E. P., Luck, C., Yu, K., Lee, A. G., Breese, M. R., Leung, S. G., Xu, H., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0873 · Cited by 45 · see citing works
Li, S.-J., Cheng, D., Zhu, B., & Yang, Q. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.19191 · Cited by 45 · see citing works
Evolving functions of Dickkopf-1 in cancer and immunity
Jaschke, N., Hofbauer, L. C., Göbel, A., & Rachner, T. D. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.03.031 · Cited by 44 · see citing works
Martins‐Neves, S. R., Sampaio-Ribeiro, G., & Gomes, C. M. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098401 · Cited by 43 · see citing works
Patient Derived Xenografts for Genome-Driven Therapy of Osteosarcoma
Landuzzi, L., Manara, M. C., Lollini, P.-L., & Scotlandi, K. (2021) · Cells · doi:10.3390/cells10020416 · Cited by 39 · see citing works
Rodrigues, J., Sarmento, B. F. C. C., & Pereira, C. L. (2022) · In vitro models · doi:10.1007/s44164-022-00008-x · Cited by 39 · see citing works
Dai, G., Zheng, D., Wang, Q., Yang, J., Liu, G., Song, Q., Sun, X., Tao, C., Hu, Q., Gao, T., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20987 · Cited by 36 · see citing works
Jacques, C., Renema, N., Lézot, F., Ory, B., Walkley, C. R., Grigoriadis, A. E., & Heymann, D. (2018) · Journal of bone oncology · doi:10.1016/j.jbo.2018.02.004 · Cited by 36 · see citing works
Modulating Dickkopf-1: A Strategy to Monitor or Treat Cancer?
Mazon, M., Masi, D., & Carreau, M. (2016) · Cancers · doi:10.3390/cancers8070062 · Cited by 32 · see citing works
Patient-derived xenograft models in musculoskeletal malignancies
Wan, L., Chao, T., Chen, R., Su, J., & Li, Z. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1487-6 · Cited by 32 · see citing works
Schott, C. R., Shah, A. T., & Sweet-Cordero, A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43085-6_1 · Cited by 30 · see citing works
CAR T targets and microenvironmental barriers of osteosarcoma
Zhu, J., Simayi, N., Wan, R., & Huang, W. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2021.12.010 · Cited by 27 · see citing works
Danieau, G., Morice, S., Renault, S., Brion, R., Biteau, K., Amiaud, J., Cadé, M., Heymann, D., Lézot, F., Verrecchia, F., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14050421 · Cited by 24 · see citing works
Hosseini, F., Alemi, F., Malakoti, F., Mahmoodpoor, A., Younesi, S., Yousefi, B., & Asemi, Z. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114758 · Cited by 23 · see citing works
Han, W., & Liu, J. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.07.049 · Cited by 21 · see citing works
Dickkopf Proteins and Their Role in Cancer: A Family of Wnt Antagonists with a Dual Role
Giralt, I., Gallo-Oller, G., Navarro, N., Zarzosa, P., Pons, G., Magdaleno, A., Segura, M. F., de Toledo, J. S., Moreno, L., Gallego, S., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14080810 · Cited by 21 · see citing works
Membrane‐bound Dickkopf‐1 in Foxp3+ regulatory T cells suppresses T‐cell‐mediated autoimmune colitis
Chae, W., Park, J., Henegariu, O., Yılmaz, S., Hao, L., & Bothwell, A. L. M. (2017) · Immunology · doi:10.1111/imm.12766 · Cited by 20 · see citing works
Lan, M., Zhu, X.-P., Cao, Z.-Y., Liu, J.-M., Lin, Q., & Liu, Z.-L. (2018) · Journal of Bone Oncology · doi:10.1016/j.jbo.2018.07.010 · Cited by 19 · see citing works
Ding, F.-P., Tian, J., Wu, J., Han, D., & Zhao, D. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02308-w · Cited by 18 · see citing works
Bravo, D., Shogren, K. L., Zuo, D., Wagner, E. R., Sarkar, G., Yaszemski, M. J., & Maran, A. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25809 · Cited by 17 · see citing works
Li, S., Liu, F., Pei, Y., Wang, W., Zheng, K., & Zhang, X. (2019) · Aging · doi:10.18632/aging.102280 · Cited by 17 · see citing works
Huang, L., Ying, H., Chen, Z., Zhu, Y., Gu, Y., Hu, L., Chen, D., & Zhong, N. A. (2019) · Placenta · doi:10.1016/j.placenta.2019.03.001 · Cited by 17 · see citing works
Martinez-Font, E., Felipe‐Abrio, I., Fariñas, S. C., Ramos, R. F., Terrasa, J., Vögler, O., Alemany, R., Martín‐Broto, J., & Obrador‐Hevia, A. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0585 · Cited by 16 · see citing works
McNeill, E. P., Reese, R. W., Tondon, A., Clough, B. H., Pan, S., Froese, J. J., Palmer, D. H., Krause, U., Loeb, D. M., Kaunas, R. R., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1203-8 · Cited by 16 · see citing works
Self-citationCaldwell, C., Rottman, J. B., Paces, W., Bueche, E., Reitsma, S., Gibb, J., Adisetiyo, V., Haas, M., Heath, H., Newman, W., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-89060-3 · Cited by 16 · see citing works
Dkk1 Controls Cell-Cell Interaction through Regulation of Non-nuclear β-Catenin Pools
Johansson, M., Giger, F. A., Fielding, T., & Houart, C. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.10.026 · Cited by 16 · see citing works
Pan, S., Cesarek, M. R., Godoy, C., Co, C. M., Schindler, C., Padilla, K., Haskell, A. W., Barreda, H., Story, C., Poole, R., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01764-z · Cited by 13 · see citing works
Giralt, I., Gallo-Oller, G., Navarro, N., Zarzosa, P., Pons, G., Magdaleno, A., Segura, M. F., Sábado, C., Hladun, R., Arango, D., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312921 · Cited by 12 · see citing works
Giusti, V., Miserocchi, G., Sbanchi, G., Pannella, M., Hattinger, C. M., Cesari, M., Fantoni, L., Guerrieri, A. N., Bellotti, C., Vita, A. D., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12081921 · Cited by 12 · see citing works
Unraveling Cancer’s Wnt Signaling: Dynamic Control through Protein Kinase Regulation
Tümen, D., Heumann, P., Huber, J., Hahn, N., Macek, C., Ernst, M., Kandulski, A., Kunst, C., & Gülow, K. (2024) · Cancers · doi:10.3390/cancers16152686 · Cited by 11 · see citing works
Li, S., Dong, Y., Wang, K., Wang, Z., & Zhang, X. (2017) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-017-0664-2 · Cited by 11 · see citing works
Fuloria, S., Yadav, G., Menon, S. V., Ali, H., Pant, K., Kaur, M., Deorari, M., Sekar, M., Narain, K., Kumar, S., et al. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155346 · Cited by 10 · see citing works
Decoding osteosarcoma from heterogeneity to precision therapy
Xu, Y., Bai, Y., Yang, F., Yang, B., Huang, Z., Su, L., & Peng, K. (2025) · Discover Oncology · doi:10.1007/s12672-025-04256-7 · Cited by 9 · see citing works
Factors affecting the role of canonical Wnt inhibitor Dickkopf-1 in cancer progression
Doucet, D., Brubaker, C., Turner, D., & Gregory, C. A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1114822 · Cited by 8 · see citing works
Dickkopf-1 (DKK1) drives growth and metastases in castration-resistant prostate cancer
Rinella, L., Fiorentino, G., Compagno, M., Grange, C., Cedrino, M., Marano, F., Bosco, O., Vissio, E., Delsedime, L., D’Amelio, P., et al. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00783-7 · Cited by 8 · see citing works
Effects of Drugs on Bone Quality
Imbert, L., & Boskey, A. L. (2016) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-016-9220-6 · Cited by 8 · see citing works
Targetable Intercellular Signaling Pathways Facilitate Lung Colonization in Osteosarcoma
Reinecke, J. B., & Roberts, R. D. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43085-6_7 · Cited by 7 · see citing works
Controlling Wnt Signaling Specificity and Implications for Targeting WNTs Pharmacologically
Sonavane, P. R., & Willert, K. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_529 · Cited by 7 · see citing works
Evaluation of circulating Dickkopf-1 as a prognostic biomarker in ovarian cancer patients
Klotz, D. M., Link, T., Goeckenjan, M., Wimberger, P., Poetsch, A. R., Jaschke, N., Hofbauer, L. C., Göbel, A., Rachner, T. D., & Kuhlmann, J. D. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-0504 · Cited by 7 · see citing works
Targeting WNT5B and WNT10B in osteosarcoma
Miranda‐Carboni, G. A., & Krum, S. A. (2024) · Oncotarget · doi:10.18632/oncotarget.28617 · Cited by 5 · see citing works
Inhibition of DKK-1 by WAY262611 Inhibits Osteosarcoma Metastasis
Tal, A. L., Gunawardana-Zeigler, S., Peng, D., Tan, Y., Perez, N. M., Offenbacher, R., Kastner, L., Ciero, P., Randolph, M. E., Gong, Y., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0744 · Cited by 4 · see citing works
Self-citationWang, S., Zhang, H., Chen, T., Jiang, W., Wang, F., Yu, Y., Guo, B., Xu, J. M., Yang, F., Kang, Q., et al. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101368 · Cited by 4 · see citing works
Haskell, A. W., Pan, S., Reese, R., Powers, A., Lopez, M. G., Lomeli, S., Story, C., Benton, J., Blazier, J. C., Kaunas, R. R., et al. (2025) · Scientific Reports · doi:10.1038/s41598-024-84037-4 · Cited by 3 · see citing works
The Dickkopf-1 (DKK1) Dichotomy in Oncology: New Insights on Tumor Progression and Immune Regulation
Canella, A., Gentry, Z., & Cosgrove, C. M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27093780 · Cited by 3 · see citing works
Overall review of curative impact and barriers of CAR-T cells in osteosarcoma
Li, G., Wang, H., & Meftahpour, V. (2023) · EXCLI journal · doi:10.17179/excli2023-6760 · Cited by 4 · see citing works
Wang, L., Peterson, S. M., Yang, M. L., Hernández, A. G., Yuan, T. Z., Han, Z., Prabhu, V., Chan, K. Y., Hu, C. F., Villalta, M., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03445-6 · Cited by 3 · see citing works
Ghasemi, N., Azizi, H., & Skutella, T. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1010865 · Cited by 2 · see citing works
Characterizing biomarkers in osteosarcoma metastasis based on an ego-network
Liu, Z., & Song, Y. (2017) · Biotechnology Letters · doi:10.1007/s10529-017-2305-6 · Cited by 2 · see citing works
Fu, Z., Sun, G., Li, J., & Yu, H. (2024) · Medicine · doi:10.1097/md.0000000000038470 · Cited by 3 · see citing works
Xie, Q., Shen, Y., Yang, Y., Liang, J., Wu, T., Hu, C., Wang, Y., & Tao, H. (2024) · iScience · doi:10.1016/j.isci.2024.110758 · Cited by 2 · see citing works
The Wnt Signalling Pathways: A Short Review and Specific Roles in Bone Biochemistry
Kovács, B., Nagy, E. E., Chendrean, N. N., Székely-Szentmiklósi, B., & Gyéresi, Á. (2017) · Acta Marisiensis. Seria Medica · doi:10.1515/amma-2017-0026 · Cited by 1 · see citing works
Pan, S., Cesarek, M. R., Godoy, C., Co, C. M., Schindler, C., Padilla, K., Poole, R., Dabney, A. R., & Gregory, C. A. (2021) · Research Square · doi:10.21203/rs.3.rs-677459/v1
Schott, C. R., Koehne, A. L., Sayles, L. C., Young, E. P., Luck, C., Yu, K., Lee, A. G., Breese, M. R., Leung, S. G., Xu, H., et al. (2024) · doi:10.1158/1078-0432.c.7077821.v1
Schott, C. R., Koehne, A. L., Sayles, L. C., Young, E. P., Luck, C., Yu, K., Lee, A. G., Breese, M. R., Leung, S. G., Xu, H., et al. (2024) · doi:10.1158/1078-0432.c.7077821
Ding, F., Tian, J.-Y., Wu, J., Han, D.-F., & Zhao, D. (2021) · Figshare · doi:10.6084/m9.figshare.17120444
Ding, F., Tian, J.-Y., Wu, J., Han, D.-F., & Zhao, D. (2021) · Figshare · doi:10.6084/m9.figshare.17120456
Ding, F., Tian, J.-Y., Wu, J., Han, D.-F., & Zhao, D. (2021) · Figshare · doi:10.6084/m9.figshare.17120441
Ding, F., Tian, J.-Y., Wu, J., Han, D.-F., & Zhao, D. (2021) · Figshare · doi:10.6084/m9.figshare.17120450
- Authors
- Goldstein, S. D., Trucco, M., Guzman, W. B., Hayashi, M., & Loeb, D. M.
- Affiliations
- Johns Hopkins University (US)
- Baylor College of Medicine (US)
- Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA
- Corresponding author
- Goldstein, Seth D.
- Loeb, David M.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-03-31
- Volume
- 7
- Issue
- 16
- Pages
- 21114-21123
- ISSN
- 1949-2553 (ISSN-L)
- PMC
- PMC5008272
- OpenAlex
- W2327824583
- Cited by
- 78
- References
- 33
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 10 · 2023: 4 · 2022: 5 · 2021: 15 · 2020: 8 · 2019: 5 · 2018: 7 · 2017: 14 · 2016: 3
- FWCI
- 8.64
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by
- Locations
- Oncotarget (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (U54CA168512, R01CA138212, P30CA006973)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Sarcoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- osteosarcoma, metastasis, Wnt signaling, DKK1, β-catenin, osteopontin, patient-derived xenografts, bone differentiation
- MeSH terms
- Animals, Antibodies, Monoclonal, Bone Neoplasms, Drug Evaluation, Preclinical, Female, Humans, Neoplasm Recurrence, Local, Osteosarcoma, Tumor Cells, Cultured, Biomarkers, Tumor, Mice, SCID, Mice, Inbred NOD, Apoptosis, Xenograft Model Antitumor Assays, Intercellular Signaling Peptides and Proteins, Cell Proliferation, Wnt Proteins, beta Catenin, Mice, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
